EU ADR Reporting Guidance Remains Complex, But Addresses Some Of Industry’s Concerns
Executive Summary
Europe’s drug industry trade group EFPIA says that the recently-finalized EU guideline on reporting adverse drug reactions remains complex and detailed, but it is pleased that some of the new requirements have been simplified or brought into line with international practice.